Prasterone Availability in Australia
The provided evidence does not contain specific information about prasterone's regulatory approval status or commercial availability in Australia. Based on the evidence presented, which primarily references FDA approval in the United States and EU approval, I cannot definitively confirm whether prasterone is available in Australia.
What the Evidence Shows
Regulatory Approvals Documented
The evidence clearly establishes that:
- Prasterone (intravaginal DHEA) is FDA-approved in the United States for treatment of dyspareunia due to menopause 1
- Prasterone is approved in the EU (marketed as Intrarosa®) for treatment of vulvovaginal atrophy in postmenopausal women 2
Clinical Context from Guidelines
Multiple international guidelines discuss prasterone as a treatment option:
- NCCN Guidelines (2024) recommend vaginal DHEA (prasterone) can be considered for vaginal dryness or pain with sexual activity in cancer survivors 3
- ASCO Guidelines (2018) note limited supportive data for vaginal DHEA in women with cancer history, stating "risk/benefit for this population is not fully known" 4
- International consensus statements (2023) recommend considering vaginal prasterone for vaginal atrophy and dyspareunia 5
Important Caveats About Use
Even where approved, guidelines note:
- Safety data in women with hormone-sensitive cancers remains limited 3
- Should be used with caution in patients on aromatase inhibitor therapy due to potential increases in circulating androgens 3
- Not licensed for use after breast cancer in some jurisdictions 5
Practical Recommendation
To determine prasterone availability in Australia, you should:
- Check the Australian Therapeutic Goods Administration (TGA) database directly
- Consult with local compounding pharmacies, as some countries where commercial products aren't available may allow compounded formulations
- Consider alternative evidence-based treatments for vulvovaginal atrophy that are definitively available in Australia, such as vaginal estrogen or non-hormonal moisturizers/lubricants 3, 5
The absence of Australia-specific information in these international guidelines and FDA/EU-focused drug labels suggests prasterone may not have TGA approval, but this requires direct verification with Australian regulatory authorities.